We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Centene, Quartet Extend Ties for Mental Health Solutions
Read MoreHide Full Article
Centene Corporation (CNC - Free Report) and Quartet Health have expanded their existing partnership forged in June 2019 to help members effortlessly access the behavioral health care they need.
While initially both companies served members in Illinois and Louisiana, with the extension of this alliance, they will be catering to the entire nation. The company will also be providing virtual care facilities for members who wish to access healthcare solutions from the comforts of their homes during the COVID-19 pandemic.
Remote consultation will be possible through the utilization of Quartet's national network of care options, which includes virtual tele-psychiatry and tele-therapy. Virtual care is most preferred as patient chooses to avoid health care services in person. In May 2020, nearly 80% of the appointments that Quartet scheduled for patients were for online care.
The ongoing worldwide crisis aggravated mental illness and behavioural issues. In March, more than two-thirds of Americans reportedly complained of anxiety or depression, per a McKinsey & Company survey. In April, three times as many adults reported psychological distress as they did two years prior.
Favorable industry and legislative trends also prompt Centene to deepen its toes in the behavioral market. Per a 2018 poll conducted by the Substance Abuse and Mental Health Services Administration of the U.S. Department of Health and Human Services (SAMHSA), 19.1% of adults in the United States, aged 18 years or above, registered as patients with mental illness in 2018 while 4.6% showed symptoms of a serious mental condition.
Further, approximately 7.8% people — aged 12 years or older — in 2018, required substance use treatment. According to the National Institute of Mental Health, more than 20% of adolescents, either currently or at some point in their life, had a severe debilitating mental disorder. The market for behavioral services will consistently expand on the growing awareness of mental health and substance abuse as well as treatment options available to address such complications.
Increasing awareness and a widespread social acceptance of comportemental health problems will offer health suppliers an avenue of market opportunities. Clinical developments lent an enlightened perspective to both psychological and detoxification therapies. The advancement in the behavioral health industry is driven by distant consulting and day care. Novel approaches to mental health management programs and a favorable supply-demand chain are some other factors that bode well for the behavioral healthcare market, which will aid the company’s growth eventually.
Another major player in the behavioral health care market is Acadia Healthcare (ACHC - Free Report) , which set up a unit with Tower Health to expand its reach in the industry.
The stock of Centene has gained 4.34% year to date against the industry’s decline of 4%.
The company carries a Zacks Rank #3 (Hold), currently. Better-ranked stocks in the same space include Humana Inc. (HUM - Free Report) and UnitedHealth Group Inc. (UNH - Free Report) with a Zacks Rank #2 (Buy) each at present. Earnings of the Humana and UnitedHealth company surpassed estimates in each of the trailing four quarters, the average being 10.13% and 11.64%, respectively.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Image: Shutterstock
Centene, Quartet Extend Ties for Mental Health Solutions
Centene Corporation (CNC - Free Report) and Quartet Health have expanded their existing partnership forged in June 2019 to help members effortlessly access the behavioral health care they need.
While initially both companies served members in Illinois and Louisiana, with the extension of this alliance, they will be catering to the entire nation. The company will also be providing virtual care facilities for members who wish to access healthcare solutions from the comforts of their homes during the COVID-19 pandemic.
Remote consultation will be possible through the utilization of Quartet's national network of care options, which includes virtual tele-psychiatry and tele-therapy. Virtual care is most preferred as patient chooses to avoid health care services in person. In May 2020, nearly 80% of the appointments that Quartet scheduled for patients were for online care.
The ongoing worldwide crisis aggravated mental illness and behavioural issues. In March, more than two-thirds of Americans reportedly complained of anxiety or depression, per a McKinsey & Company survey. In April, three times as many adults reported psychological distress as they did two years prior.
Favorable industry and legislative trends also prompt Centene to deepen its toes in the behavioral market. Per a 2018 poll conducted by the Substance Abuse and Mental Health Services Administration of the U.S. Department of Health and Human Services (SAMHSA), 19.1% of adults in the United States, aged 18 years or above, registered as patients with mental illness in 2018 while 4.6% showed symptoms of a serious mental condition.
Further, approximately 7.8% people — aged 12 years or older — in 2018, required substance use treatment. According to the National Institute of Mental Health, more than 20% of adolescents, either currently or at some point in their life, had a severe debilitating mental disorder. The market for behavioral services will consistently expand on the growing awareness of mental health and substance abuse as well as treatment options available to address such complications.
Increasing awareness and a widespread social acceptance of comportemental health problems will offer health suppliers an avenue of market opportunities. Clinical developments lent an enlightened perspective to both psychological and detoxification therapies. The advancement in the behavioral health industry is driven by distant consulting and day care. Novel approaches to mental health management programs and a favorable supply-demand chain are some other factors that bode well for the behavioral healthcare market, which will aid the company’s growth eventually.
Another major player in the behavioral health care market is Acadia Healthcare (ACHC - Free Report) , which set up a unit with Tower Health to expand its reach in the industry.
The stock of Centene has gained 4.34% year to date against the industry’s decline of 4%.
The company carries a Zacks Rank #3 (Hold), currently. Better-ranked stocks in the same space include Humana Inc. (HUM - Free Report) and UnitedHealth Group Inc. (UNH - Free Report) with a Zacks Rank #2 (Buy) each at present. Earnings of the Humana and UnitedHealth company surpassed estimates in each of the trailing four quarters, the average being 10.13% and 11.64%, respectively.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>